The Addario Lung Cancer Medical Institute (ALCMI) is a nonprofit organization dedicated to advancing lung cancer research. Partnering with premier oncology research institutions, ALCMI provides funding, resources, and expert teams to support investigator-initiated clinical trials in lung cancer. Their goal is to enhance the understanding of lung cancer risk factors, molecular mechanisms, and to foster therapeutic advancements to improve patient outcomes.
2008
26-1721868
$1.004 million
This organization contributes to the following United Nations Sustainable Development Goals. See the SDG page for more information.
We revolutionized remote, decentralized clinical trials that drive significant impact efficiently.
Our research has resulted in a new understanding of lung cancer genomics and novel treatment pathways.
We engage patients, advocates, and researchers to foster collaboration in lung cancer research initiatives.
November 2024
A conference focusing on the latest advancements in lung cancer treatments and research.
November 2024
Discussion on challenges and advancements in treating early-age onset cancers.
November 2024
A summit dedicated to thoracic oncology professionals to share insights and research.
Overall Score
57
50
/100
Program Expense Ratio
85.36%
16
/20
Program Revenue Growth
-35.13%
2
/20
Leverage Ratio
0.07117
20
/20
Working Capital Ratio
0.9437
10
/20
Fundraising Efficiency
0
2
/20
Fiscal Year:2022
Source:Source: Self-reported by organization
Category | Amount | Percentage |
---|---|---|
Contributions, Gifts, and Grants | 622.9K | 58.66% |
Program Services | 439K | 41.34% |
Investment Income | 90 | 0.01% |
Sales of Non-Inventory Assets | 0 | 0.00% |
Other Notable Sources | 0 | 0.00% |
Total Revenue | 1.062M | 100.00% |
Med Research
Lung Disease ResearchMed Research
Lung Disease ResearchMed Research
Lung Disease ResearchMed Research
Lung Disease ResearchMed Research
Lung Disease Research